From the above trial results, for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutant population, the combination of four drugs can bring significant survival benefits to patients with advanced NSCLC (49). The gene discussed is ALK; the disease is non-small cell lung carcinoma.